Safety
Nine treatment emergent adverse events were recorded; five in the s.c. group and four in the i.d. group. All treatment emergent adverse events were mild and self-limiting. Four subjects had fatigue, three had an upper respiratory tract infection, and one subject had a rhinitis. One subject had an injection site hematoma after i.d. adalimumab. Thus, i.d. and s.c. administration of adalimumab and saline do not raise a safety signal.